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Running head: POAG phenotype stratified by an IOP polygenic risk score 
 
Abbreviations/Acronyms: 
IOP: intraocular pressure; POAG: primary open angle glaucoma; PRS: polygenic risk score; 
ANZRAG: Australian and New Zealand Registry of Advanced Glaucoma; SD: standard 
deviation; MYOC: myocilin; OPTN: optineurin; TBK1: TANK-binding kinase 1; CI: confidence 
interval; GWAS: genome wide association study; SNP: single nucleotide polymorphism; OR: 
odds ratio; MD: mean deviation; VCDR: vertical cup-to-disc ratio; PROGRESSA: Progression 
Risk Of Glaucoma; RElevant SNPs with Significant Association; SLT: selective laser 
trabeculoplasty; IGGC: International Glaucoma Genetics Consortium.  
Abstract 
Objective: To examine the combined effects of common genetic variants associated with 
intraocular pressure (IOP) on primary open angle glaucoma (POAG) phenotype using a 
polygenic risk score (PRS) stratification. 
Design: Cross-sectional study. 
Participants: For the primary analysis, we examined the glaucoma phenotype of 2,154 
POAG patients enrolled in the Australian and New Zealand Registry of Advanced Glaucoma 
(ANZRAG) including cases recruited from the UK. For replication, we examined an 
independent cohort of 624 early POAG patients. 
Methods: Using IOP genome-wide association study summary statistics, we developed a 
PRS derived solely from IOP associated variants and stratified POAG patients into three risk 
tiers. The lowest and highest quintiles of the score were set as the low and high risk groups 
respectively and the other quintiles as the intermediate risk group. 
Main Outcome Measures: Clinical glaucoma phenotype including maximum recorded IOP, 
age of diagnosis, number of family members affected by glaucoma, cup-to-disc ratio, visual 
field mean deviation, and treatment intensity. 
Results: There was a dose-response relationship between the IOP PRS and the maximum 
recorded IOP, with the high genetic risk group having a higher maximum IOP by 1.7 (SD 
0.62) mmHg than the low genetic risk group (P = 0.006). Compared to the low genetic risk 
group, the high genetic risk group had a younger age of diagnosis by 3.7 (1.0) years (P < 
0.001), more family members affected by 0.46 (0.11) members (P < 0.001), and higher rates 
of incisional surgery (odds ratio 1.5; 95% confidence interval 1.1 - 2.0; P = 0.007). There 
was no statistically significant difference in mean deviation. We further replicated the 
maximum IOP, number of family members affected by glaucoma and treatment intensity 
(number of medications) results in the early POAG cohort (P ≤ 0.01). 
Conclusions: The IOP polygenic risk score was positively correlated with maximum IOP, 
disease severity, need for surgery and number of family members. Genes acting via IOP 
mediated pathways, when considered in aggregate have clinically important and 
reproducible implications for glaucoma patients and their close family members. 
  
Glaucoma refers to a group of progressive optic neuropathies with a characteristic pattern of 
retinal ganglion cell death and visual field loss.1 Intraocular pressure (IOP) is currently the only 
proven modifiable risk factor for primary open angle glaucoma (POAG), in which the 
iridocorneal angle is open and there is no secondary cause of IOP elevation.2 Despite this, 
elevated IOP is not essential for the diagnosis of POAG, nor is it effective for screening for 
glaucoma.1,3 The current methods of IOP assessment are limited to the time of measurement 
and are a poor measure of an individual’s IOP profile, maximum and fluctuations. Additional 
IOP measurements are more informative for glaucoma management as both diurnal and long-
term IOP fluctuations have been reportedly associated with glaucoma progression.4,5 
 
Glaucoma is highly heritable and several genes with a Mendelian pattern of inheritance have 
been associated with POAG.6 Monogenic variants causing glaucoma are relatively rare but 
carry a high risk of developing the disease. Family-based genetic linkage analysis has 
identified three genes associated with Mendelian glaucoma; myocilin (MYOC), optineurin 
(OPTN) and TANK-binding kinase 1 (TBK1) genes.7–10 Pathogenic variants in the MYOC gene 
account for 2-4% of adult-onset POAG.10 The most common pathogenic variant in the MYOC 
gene in individuals of European ancestry (p.Gln368Ter) has a minor allele frequency of 0.13%, 
yet carries a significant risk of glaucoma with high IOP in those who carry it (in a population 
based setting odds ratio [OR] = 6.76 with 95% confidence interval [CI] of 4.05-11.29).11 In 
family-based studies, the penetrance of p.Gln368Ter to manifest POAG is reported at 
approximately 80% by the seventh decade of life.11 
 
IOP in the normal population is a polygenic trait, with recent large genome-wide association 
studies (GWAS) discovering more than one hundred common loci associated with IOP, 
accounting for 40% of the heritability.12–14 Khawaja et al. reported that these single nucleotide 
polymorphisms (SNPs) explained 17% of IOP variance in an independent clinical study, and 
9% in the UK biobank study which likely reflects the difference in IOP measurement methods.14 
In contrast to the aforementioned monogenic variants, each SNP contributes a very small 
effect size. For instance, variants in or near the genes TMCO1 and CAV2, two of the most 
strongly associated loci with IOP and glaucoma, are present in 10-15% of the population but 
account for a modest risk of glaucoma individually (OR 1.1 - 1.4).12–14 However, the combined 
effects of these common SNPs significantly affect the observed clinical phenotype.12  
 
To understand the impact of these common variants, we consider the total number of variants 
an individual is carrying multiplied by their effect size, to generate a weighted polygenic risk 
score (PRS).15 A genetic risk stratification may then be done by calculating an aggregate score 
of all the SNPs an individual has associated with a trait. For instance, a person with the 
majority of the discovered IOP variants (a high IOP PRS) is hypothesised to have a higher 
IOP than someone who has only a few. The PRS model of risk prediction has been used to 
stratify individualised disease risk in several medical conditions such as coronary artery 
disease, atrial fibrillation and breast cancer.16–18 Recently, a PRS derived from the known IOP 
variants has been reported to account for a higher risk of developing glaucoma;12 however, 
the influence of the IOP PRS on a wider range of glaucoma-related phenotypes has not been 
described. In this study, we aimed to characterise the clinical features of glaucoma patients 
with a high burden of IOP associated variants in a large national Australian glaucoma registry 
along with ethnically similar cases from the UK. 
Methods 
Study participants 
The study adhered to the tenets of the Declaration of Helsinki and followed the National Health 
and Medical Research Council statement of ethical conduct in research involving humans. 
Informed consent was obtained from all participants, and the study was approved by the 
Southern Adelaide Clinical Human Research Ethics Committee. 
 
The study participants were enrolled in the Australian and New Zealand Registry of Advanced 
Glaucoma (ANZRAG).19 The study includes both advanced and non-advanced glaucoma 
cases. Advanced glaucoma was defined by a Humphrey 24-2 visual field mean deviation (MD) 
< -15 dB in the worse eye, or loss of at least two of the central visual field points on the pattern 
deviation map.19 Non-advanced glaucoma was defined by optic nerve head changes with 
corresponding visual field defects consistent with glaucoma, but not fitting the aforementioned 
criteria. The study sample included additional ethnically matched advanced glaucoma cases 
recruited from the UK.20 Only patients of European ancestry with POAG were included to utilise 
the currently published IOP SNPs. Patients with variants in the known POAG genes (MYOC, 
OPTN and TBK1) were excluded. The highest IOP measurement recorded with Goldmann 
applanation tonometry by the referring ophthalmologist before treatment of either eye for each 
participant was recorded. High tension glaucoma was defined as a maximum recorded IOP > 
21 mmHg. Other data recorded at the time of recruitment included age at diagnosis, vertical 
cup-to-disc ratio (VCDR), and glaucoma surgery. Family history was self-reported and 
recorded for affected relatives up to the fourth degree by the referring clinician. Where 
applicable, the family tree of affected individuals was recorded and reviewed by the registry 
staff before recording the number of family members affected by glaucoma in the registry. 
 
An independent cohort of early glaucoma patients enrolled in the Progression Risk Of 
Glaucoma; RElevant SNPs with Significant Association (PROGRESSA) study were then used 
for replication. Only participants with established perimetric glaucoma, defined by two 
consecutive reliable visual field examinations with Glaucoma Hemifield Test “Outside Normal 
Limits”, pattern standard deviation <5%, or a cluster of 3 contiguous points depressed <5% in 
the pattern standard deviation map, at least one of which is  <1%, were included. Data 
recorded included self-reported family history of glaucoma, maximum IOP recorded at any 
visit, VCDR and visual field at the last visit, number of topical glaucoma medications and 
previous selective laser trabeculoplasty (SLT). The number of topical medications and SLT 
are routinely updated at each visit for this cohort. A small proportion (2.4%) have had an 
incisional surgery for the management of their glaucoma which would significantly alter their 
medical management. Thus for the medical treatment analysis, we have used the highest 
number of drops at any one appointment for each patient.  
Polygenic risk score 
The IOP derived PRS was comprised of 146 statistically independent genome-wide-significant 
SNPs (P value threshold at 5×10-8 and LD-clumping at r2 = 0.1) as reported previously 
(Supplementary Table 1).12 Briefly, SNPs influencing IOP were discovered by a GWAS of 
cornea-compensated IOP measured by Ocular Response Analyzer in participants of the UK 
Biobank study (N = 103,914).12,21 This was meta-analysed with GWAS results from the 
International Glaucoma Genetics Consortium (IGGC, N = 29,578) using the inverse variance 
weighted method (METAL software).22 A weighted PRS was then derived for each individual 
in the ANZRAG study cohort using PLINK (version 1.90 beta),23 taking into account the effect 
size of each SNP using the UK Biobank GWAS summary statistics. None of the study 
participants in ANZRAG or PROGRESSA were part of the discovery cohort. A percentile score 
was then derived within the ANZRAG and the PROGRESSA cohorts. We classified patients 
into three risk groups; the top 20% of the genetic risk score were classified as the high risk 
group; the middle 60% as the intermediate risk group; and the bottom 20% as the low risk 
group. Additionally, we calculated the recently published 12-SNP unweighted POAG PRS by 
Fan et al. for our primary cohort for comparision.24 A detailed comparison between these 
scores is presented summarised in Supplementary Table 2. Genotyping was done in several 
phases on either Illumina Omni1M, OmniExpress or HumanCoreExome arrays (Illumina, San 
Diego, CA, USA) as described previously.12 
Statistical analysis 
The Shapiro-Wilk test was used to assess for normality. Analysis of variance of continuous 
variables by PRS groups was done using Kruskal–Wallis test. Count and categorical variables 
were compared using Pearson's chi-squared test. For two-group comparisons, the Mann-
Whitney U test was used. Logistic regression models were fitted for binary outcomes and 
negative binomial regression was used for count data (number of family members affected). 
Linear regression using the continuous numerical PRS as the explanatory variable was used 
to compare the aforementioned two scores. All analysis was done using R (version 3.5.1, 
RCore Team, Austria).25 The significance level (alpha) was set at 0.05. 
Results 
A total of 2,154 eligible POAG patients from ANZRAG with mean age at recruitment of 77.4 
(SD 13.2) years were included. The majority of the study cohort (N = 1,664; 77%) had 
advanced glaucoma as defined above. This included 381 cases recruited from the UK (N = 
290 from Southampton and N = 91 Liverpool) who were ethnically matched to the rest of the 
cohort. A summary of the glaucoma phenotype across the three genetic risk groups is 
summarised in Table 1. 
 
The high IOP genetic risk group had a significantly higher maximum IOP by 1.3 mmHg (95%CI: 
0.32 - 2.7 mmHg; P = 5.5x10-3) compared to the intermediate and low genetic risk groups. The 
maximum IOP was not statistically significantly different in the intermediate group relative to 
the low risk group (mean difference of 0.54 mmHg, 95% CI -1.5 - 0.47 mmHg; P = 0.08). 
Similarly, the high genetic risk group was more likely to present as high tension glaucoma, 
defined by a maximum IOP above 21 mmHg (OR = 1.9; 95% CI 1.3 - 2.8; P = 7.9x10-4 relative 
to the low-risk group). Further analysis by decile groups of the IOP PRS shows a continuous 
variant dose-response relationship between higher IOP PRS and maximum IOP, signifying 
the cumulative effects of the common IOP variants (Figure 1A). 
 
The mean age of glaucoma diagnosis was significantly different across the genetic risk groups 
(P = 1.3x10-4). The high genetic risk group were diagnosed with glaucoma on average 2.2 (SD 
0.80) years earlier than the intermediate group (P = 5.5x10-3) and 3.7 (SD 1.0) years than the 
low genetic risk group (2.4x10-4). The high risk group were more likely to have family members 
affected by glaucoma relative to the low risk group (OR = 1.6, 95% CI 1.2 - 2.1. P = 1.1x10-3). 
The number of self-reported family members affected by glaucoma was also higher in the high 
IOP PRS group compared to the intermediate (mean 0.29, SD 0.1, P = 5.2x10-3) and low risk 
groups (mean 0.46, SD 0.11, P = 1.8x10-4). Furthermore, there was a linear relationship 
between the IOP PRS and the number of family members affected by glaucoma which 
highlights the importance of these variants and their impact on the development of glaucoma 
(Figure 1B). 
 
There was no significant difference between the Humphrey visual field mean deviation 
between the IOP PRS groups P = 0.18). However, the high genetic risk group were more likely 
to require an incisional surgery for the management of their glaucoma relative to the 
intermediate and low risk groups (OR = 1.3, 95% CI = 1.0 - 1.6; P = 0.049 and OR = 1.5; 95% 
CI  = 1.1 - 2.0; P = 7.9x10-3 respectively). Further, the high IOP PRS group were more likely 
to require bilateral incisional surgeries than the intermediate and low risk groups (OR = 1.4, 
95% CI = 1.0 - 1.8; P = 0.02). 
 
For replication, we stratified an independent cohort of early perimetric POAG patients (N = 
624), with an average age of 69.5 (10) years, into three risk groups based on the same 
absolute numerical IOP PRS cut-off used above. There was a similar association of increasing 
maximum IOP, number of family members affected, and treatment intensity (Table 2 and 
Figure 2). The high risk group had more than twice as many family members affected as the 
low risk group, and were more likely to require more intensive medical therapy to control their 
disease (P ≤ 0.01). There was no significant association between the PRS and the length of 
follow-up (P = 0.65). 
 
A recently reported PRS associated with POAG in European white populations was associated 
with a younger age of glaucoma diagnosis.24 For comparison, we calculated this PRS in our 
primary cohort (ANZRAG, n = 2,154; Supplementary Table 2). The IOP PRS presented in this 
study was more strongly associated with the age of glaucoma diagnosis (P = 2.0x10-5) than 
the 12-SNP PRS reported by Fan et al. (P = 2.6 x 10-4) and explained a greater variance of 
this outcome (R2 of linear regression 0.89% vs 0.65% respectively; Supplementary Table 3). 
The 12-SNP PRS was not associated with the maximum IOP recorded (P = 0.45), and 
explained less variance in the need for incisional surgery outcome compared to the IOP PRS 
(R2 of linear regression 0.53% vs 0.79% respectively; Supplementary Table 3). Due to the 
inclusion of two VCDR-associated POAG risk variants near CDKN2B-AS1 and SIX6, the 12-
SNP PRS was associated with a higher VCDR but not the IOP PRS (Supplementary Table 3). 
Discussion 
Common genetic variants associated with both glaucoma and IOP have been identified via 
genome-wide association studies. Genetic risk score stratification can be used to estimate the 
combined effect size of these variants on the patient. In this study, glaucoma patients in the 
high IOP genetic risk group had a higher maximum (pre-treatment) IOP, younger age of 
glaucoma diagnosis, and were more likely to require incisional surgery to control their disease 
than those in the intermediate or low IOP genetic risk groups. We have further replicated these 
results in an independent cohort of early glaucoma patients and observed a similar association 
with the higher genetic risk group requiring more intensive medical therapy for glaucoma 
management. 
 
Interestingly, despite the clinically modest difference in the maximum IOP between the high 
and low IOP genetic risk groups (between 1-2 mmHg in two independent cohorts), we 
observed a stronger relationship in treatment intensity. In the ANZRAG cohort, the incisional 
surgery rate was 50% in the high genetic risk group compared to 38% in the low risk group. 
Similarly, in the early glaucoma cohort, 38% of the high genetic risk group required 2 or more 
medications or SLT for glaucoma management compared to 23% in the low genetic risk group. 
Thus, IOP genetic risk variants and stratification may offer further insight into an individual's 
chronic exposure to higher IOP than sporadic clinic measurements. Further, these risk variants 
confer increased risk of developing POAG in carriers,12 thus patients with higher polygenic risk 
scores had significantly more family members affected by glaucoma. 
 
TMCO1 was one of the earliest reported genes to be associated with POAG in common variant 
studies, and remains one of the most strongly associated variants with IOP and POAG.12,14,26 
A variant in TMCO1 gene is reportedly associated with conversion from ocular hypertension 
to glaucoma in non-Hispanic whites27 In another study, individuals homozygous for a variant 
near TMCO1 were reported to have a younger age of POAG onset.28 However, the clinical 
utility of genetic risk scores is expanding due to the accelerated discovery of disease-
associated loci as larger genome-wide association studies are conducted. While early studies 
on using genetic risk scores for POAG were limited,29,30 Macgregor et al. have recently 
reported an IOP based genetic risk score accounting for a significant risk of developing 
glaucoma (OR = 5.6 in the highest decile of the score relative to the lowest).12 Fan et al. 
reported a PRS inclusive of 12-SNPs associated with POAG to be associated with a younger 
age of glaucoma diagnosis.24 This PRS was inclusive of two variants near CDKN2B-AS1 and 
SIX6 associated with POAG and VCDR but not IOP,7,24,26 which in addition to the low number 
of variants used in the score, may account for why this PRS was not associated with the 
maximum IOP phenotype in our study cohort. This supports the fact that inclusion of additional 
low impact variants leads to better PRS models for complex traits.31 Further research is 
needed on a more comprehensive PRS inclusive of variants associated with POAG and its 
endophenotypes.  
 
Conversely, the effects of Mendelian variants on glaucoma phenotype have been well 
described. Pathogenic variants in the MYOC gene are most commonly associated with high 
IOP and more advanced disease.32 In contrast, duplications and triplications involving TBK1 
and missense variants in OPTN cause familial normal tension glaucoma, and are typically not 
found in high tension glaucoma.7–9 While these genes are important in familial glaucoma and 
highly predictive of disease risk, they are a relatively rare cause of POAG in the general 
population. Thus, genetic risk stratification using common variants of IOP is more widely 
applicable to most POAG patients. Our results show that the cumulative effect of IOP-
associated genetic variants may predict an individual's lifetime IOP exposure, and support the 
utility of genetic risk scores in POAG monitoring. Further, PRS risk stratification can be done 
before the clinical presentation of the disease, and therefore may be useful for identifying high-
risk individuals for screening. To our knowledge, this is the first study to detail the clinical 
glaucoma phenotype based on the combined effect of common IOP variants. 
 
This study has several strengths. We utilised the large UK Biobank cohort to derive a genetic 
risk score of corneal compensated IOP. Using this score inclusive of variants at a strict 
genome-wide threshold, we characterised the clinical glaucoma phenotype that is attributable 
to the genetic biomarkers of IOP and its associated pathways. Inclusion of additional POAG 
risk and other endophenotype variants may yield a better glaucoma risk profiling. Our study 
cohort was also independent allowing validation of the discovered variants. We have further 
replicated our findings in another independent POAG cohort with mild glaucoma allowing 
further generalisability across the glaucoma severity spectrum. Our study has also some 
limitations. There may inter-clinician variability in the rate of incisional surgeries as this was 
not done per protocol. A mixed-effects model with the referring clinician as a random-effect 
intercept yielded similar results in the estimated effect size of the IOP PRS on incisional 
surgery risk. Patient-reported family members affected has not been validated in a glaucoma 
setting and may lack sensitivity and specificity. While our replication of this finding in an 
independent sample suggests plausible correlation, the effect size may be under or 
overestimated due to recall and survival biases and community under-diagnosis of glaucoma. 
Genetic risk scores are limited by the genetic pool of the discovery cohort. Our results are 
limited to the ethnicities of the European ancestry individuals of the UK Biobank study which 
matched our prediction target cohort. Validation is needed in other ethnicities. We have only 
used SNPs that reached genome-wide significance in the GWAS to calculate the PRS. While 
the inclusion of additional SNPs would include further low-impact susceptibility SNPs, it would 
also introduce further ‘noise’ to the PRS and may not improve risk stratification.33 
 
In conclusion, our IOP PRS correlates with the maximum recorded IOP and glaucoma 
severity of POAG patients in a national glaucoma registry. Our result supports the clinical 
utility of PRS in POAG risk stratification. 
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Figure legends: 
Figure 1. A continuous variant dose-response relationship between IOP PRS and (A) the 
maximum recorded IOP in the ANZRAG cohort (P = 1.9x10-3 for linear model trend); (B) the 
mean number of family members affected by glaucoma (P = 1.3x10-5 for negative binomial 
generalised linear model trend). The squares represent the mean values for each PRS decile 
group, and the error bars represent the 95% confidence interval of the mean. The grey line is 
the line of best fit with the 95% confidence interval lightly shaded around the line. 
IOP: intraocular pressure;  PRS: polygenic risk score. 
 
Figure 2. Replication of the (A) maximum IOP recorded (P = 5.0x10-4 for one-way analysis of 
variance) and (B) the number of family members affected by glaucoma (P = 1.0x10-3 for one-
way analysis of variance) in an independent cohort of early POAG patients (N = 624). The 
squares represent the mean values for each PRS group, and the error bars represent the 95% 
confidence interval of the mean. 
IOP: intraocular pressure;  PRS: polygenic risk score; POAG: primary open angle glaucoma. 
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